^
    1d
    Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=58, Terminated, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Terminated; Adjusted the product development strategy.
    Trial termination
    1d
    U96-CAR-T-Cells For R/R B-ALL (clinicaltrials.gov)
    P1, N=30, Recruiting, The First Affiliated Hospital of Soochow University
    New P1 trial
    |
    CD20 negative
    1d
    WATCH Tranfuse: WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, University of Oxford
    New trial • HEOR
    1d
    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies (clinicaltrials.gov)
    P=N/A, N=5000, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting
    Enrollment closed
    1d
    A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy (clinicaltrials.gov)
    P=N/A, N=320, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    1d
    Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (clinicaltrials.gov)
    P=N/A, N=30, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    1d
    Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Northside Hospital, Inc.
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • decitabine • Niktimvo (axatilimab-csfr)
    1d
    Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia (clinicaltrials.gov)
    P2, N=204, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    1d
    ALLight: Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=83, Recruiting, AstraZeneca
    Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    1d
    A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Venclexta (venetoclax) • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2d
    Comparative evaluation of two NGS-based assays for somatic hypermutation analysis of IGHV genes in chronic lymphocytic leukemia. (PubMed, Blood Res)
    These findings indicate that the Leader assay provides a more reliable assessment of SHM status, with higher concordance with SS. Although the FR1 assay may offer additional information regarding clonal patterns, its results should be interpreted cautiously. Given the limited sample size, further studies are warranted to validate these findings. Overall, the Leader assay appears to be more suitable as a primary tool for SHM evaluation, with FR1 results serving a complementary role when interpreted in clinical context.
    Journal • Next-generation sequencing
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    LymphoTrack® Dx IGH Assay